Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum gold determinations in patients with rheumatoid arthritis receiving sodium aurothiomalate.

× No keyword cloud information.

12 in total

1. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors:
Journal: Ann Rheum Dis Date: 1959-03 Impact factor: 19.103

2. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors: C M PLOTZ; J M SINGER
Journal: Am J Med Date: 1956-12 Impact factor: 4.965

3. METABOLISM, TOXICITY AND MANNER OF ACTION OF GOLD COMPOUNDS USED IN THE TREATMENT OF ARTHRITIS. I. HUMAN PLASMA AND SYNOVIAL FLUID CONCENTRATION AND URINARY EXCRETION OF GOLD DURING AND FOLLOWING TREATMENT WITH GOLD SODIUM THIOMALATE, GOLD SODIUM THIOSULFATE, AND COLLOIDAL GOLD SULFIDE.

Authors: R H Freyberg; W D Block; S Levey
Journal: J Clin Invest Date: 1941-07 Impact factor: 14.808

4. Studies with radioactive gold.

Authors: J S LAWRENCE
Journal: Ann Rheum Dis Date: 1961-12 Impact factor: 19.103

5. Observations on the eosinophilia of certain patients with rheumatoid arthritis.

Authors: R J Winchester; D Koffler; S D Litwin; H G Kunkel
Journal: Arthritis Rheum Date: 1971 Sep-Oct

6. The present status of chrysotherapy.

Authors: J D Jessop
Journal: Practitioner Date: 1972-01

7. Plasma gold estimations in patients receiving chrysotherapy for rheumatoid arthritis.

Authors: D J Pole; N D Balazs; J Maserai
Journal: Med J Aust Date: 1971-12-04 Impact factor: 7.738

8. Gold determination in biological fluids by atomic absorption spectrophotometry: application to chrysotherapy in rheumatoid arthritis patients.

Authors: A Lorber; R L Cohen; C C Chang; H E Anderson
Journal: Arthritis Rheum Date: 1968-04

9. Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis.

Authors: F E Krusius; A Markkanen; P Peltola
Journal: Ann Rheum Dis Date: 1970-05 Impact factor: 19.103

10. Gold nephropathy. A clinical and pathologic study.

Authors: D S Silverberg; E G Kidd; T K Shnitka; R A Ulan
Journal: Arthritis Rheum Date: 1970 Nov-Dec

17 in total

1. Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro.

Authors: C J Danpure; D A Fyfe; J M Gumpel
Journal: Ann Rheum Dis Date: 1979-08 Impact factor: 19.103

9. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.

Authors: K Hashimoto; C E Whitehurst; T Matsubara; K Hirohata; P E Lipsky
Journal: J Clin Invest Date: 1992-06 Impact factor: 14.808

10. Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds.

Authors: P E Lipsky; M Ziff
Journal: J Clin Invest Date: 1977-03 Impact factor: 14.808

Serum gold determinations in patients with rheumatoid arthritis receiving sodium aurothiomalate.

1. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

2. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

3. METABOLISM, TOXICITY AND MANNER OF ACTION OF GOLD COMPOUNDS USED IN THE TREATMENT OF ARTHRITIS. I. HUMAN PLASMA AND SYNOVIAL FLUID CONCENTRATION AND URINARY EXCRETION OF GOLD DURING AND FOLLOWING TREATMENT WITH GOLD SODIUM THIOMALATE, GOLD SODIUM THIOSULFATE, AND COLLOIDAL GOLD SULFIDE.

4. Studies with radioactive gold.

5. Observations on the eosinophilia of certain patients with rheumatoid arthritis.

6. The present status of chrysotherapy.

7. Plasma gold estimations in patients receiving chrysotherapy for rheumatoid arthritis.

8. Gold determination in biological fluids by atomic absorption spectrophotometry: application to chrysotherapy in rheumatoid arthritis patients.

9. Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis.

10. Gold nephropathy. A clinical and pathologic study.

1. Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro.

2. Proceedings: A serial study of eosinophilia and raised IgE antibodies during gold therapy.

3. Binding of sodium aurothiomalate to human serum albumin in vitro at physiological conditions.

4. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity.

5. Serum gold concentrations during treatment with auranofin.

Review 6. Monitoring gold plasma levels in rheumatoid arthritis.

Review 7. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

8. Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST).

9. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.

10. Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds.